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Abstract 
The Philadelphia negative myeloproliferative neoplasms include Polycythaemia 
Vera (PV), Essential Thrombocytopenia(ET) and Primary Myelofibrosis(PMF). 
Patients with these conditions were mainly thought to harbour JAK2V617F 
mutations or an MPL substitution.  In 2013 two revolutionary studies identified 
recurrent mutations in a gene which encodes the protein calreticulin. (CALR).  
This mutation was detected in patients with PMF and ET with non mutated 
JAK2  or MPL but was absent in patients with PV.  The CALR gene encodes the 
calreticulin protein, which is a multifactorial protein, mainly located in the 
endoplasmic reticulum in chromosome 19 and regulates calcium homeostasis, 
chaperones and has also been implicated in multiple cellular processes including 
cell signalling, regulation of gene expression, cell adhesion, autoimmunity and 
apoptosis. Somatic 52-bp deletions and recurrent 52-bp insertion mutations in 
CALR were detected and all resulted in frameshift and clusters in exon 9 of the 
gene. This review will summarise the current knowledge on the CALR gene and 
mutation of the gene in pathological conditions and patient phenotypes.  
 
Localisation of the CALR Gene 
Calreticulin is a ubiquitous protein which is present in all eukaryotic cells 
except erythrocytes as these lack endoplasmic reticulum. (1) This protein is 
encoded in humans by the Calreticulin (CALR) gene.  Through detailed analysis 
of somatic cell hybrids, it was found that CALR gene is located on chromosome 
19 (2). To date two CALR genes have been identified – CALR 1 and CALR 2. 
The exact function of CALR 2 gene has yet to be determined. The CALR 1 gene 
encodes the 46KDa protein (4). In humans, the CALR gene spans 4.6kb of the 
genomic DNA and is composed of nine exons. (5,6) and eight introns (3). The 
CALR protein has been found to have Ro/SSA ribonucleoprotein complex 
properties. Itoh et al found that within the CALR gene, separate genes encode 
the 60-kd form and the 52 –kd forms of Ro/SSA antoantibodies subsequently 
mapping to chromosome 1 (TROVE2;600063) and chromosome 11 
(TRIM21;109092) respectively. (5,7)   
 
 
Structure 
A. The CALR gene 
This gene is made up of nine exons and eight introns (3). It spans 3.6kb of 
human genomic DNA(5) (Figure 1). It exists as a single copy on chromosome 19. 
(15) The promoter sites of the CALR gene contain several putative regulatory 
sites which include AP-1 and AP-2 sites, GC rich areas which include an Sp1 
site, a H4TF-1 site and also four CCAAT sequences (5). Both H4TF-1 and AP-2 
recognition sequences have been found in genes which are active in cellular 
proliferation.(9) 
B. Calreticulin Protein  
The calreticulin (CALR) protein is a multifactorial protein which is localised to 
the intracellular, cell surface and extracellular compartments. It regulates a wide 
variety of biological processes including antigen processing and presentation to 
the adaptive immune system, cellular proliferation, cell adhesion, uptake of 
CALR expressing cancer cells by dendritic cells and phagocytosis of apoptotic 
cells. It contains three main structural domains: (10) 
1. The first third of the protein is called the N Terminal. (8) N terminal is 
responsible for interactions with other proteins and the C terminal (10). 
This domain contains eight anti-parallel β strands and interacts with the 
DNA binding site of steroid receptors and α integrins. Additionally the 
disulphide bonds formed by cysteine residues within this domain have 
been found to interact with the P domain to form the vital chaperone 
function of CALR. (11) 
2. The second third of the protein is the P Domain. This proline rich P 
domain contains two sets of three repetitive amino acid sequence regions. 
These regions form lectin like structures which are responsible for the 
protein folding function of CALR (11). This domain contains a region that 
binds calcium with high affinity 12). It also contains several KPEDWU 
repeats, several ‘PEST’ regions and a putative nuclear localisation signal. 
(8) 
3. Finally, the C terminus is rich in acidic amino acids and contains multiple 
calcium binding sites. It is a highly acidic region (11) and 37 of the final 57 
residues are aspartic or glutamic acid (8).  This domain regulates the 
calcium levels within the endoplasmic reticulum (ER). It binds to calcium 
with high capacity and low affinity. (11) This terminus contains a four 
amino acid (lysine, aspartate, glutamate and leucine) KDEL ER retention 
motif which prevents CALR from being secreted from the ER (12). These 
three domains are illustrated in Figure 2.  
 
The CALR promoter region contains multiple binding sites for transcription 
factors. Many of these factors have been identified as essential modulators for 
CALR expression including NKx2.5 which encodes a homeobox-containing 
transcription factor and defects of which can result in Tetralogy of Fallot, atrial 
septal defects with atrioventricular conduction defects and congenital 
hypothyroidism(13). MEF2C is a transcription activator and is present in the 
regulatory regions of multiple muscle specific genes. It binds specifically to the 
MEF2 element within these genes. It is involved in vascular development and 
cardiac morphogenesis and myogenesis (14), GATA6 (a member of the zinc 
transcription factor family which plays a vital role in organogenesis and cellular 
differentiation during vertebral  development (15)  , and Evi-1 an oncoprotein and 
transcription factor which is involved in cell differentiation, apoptosis, 
proliferation, cellular development and haematopoiesis (11,16).  
Biological Functions of CALR protein  
(A) Intracellularly 
CALR acts as a major calcium binding protein within the lumen of the 
endoplasmic reticulum, it binds >50% of calcium present in the ER (12). In doing 
so it ensures newly synthesised proteins are correctly folded, become 
proteosome resistant and therefore enables the proteins to carry out their 
required intracellular function. (12). CALR protein has been found to regulate 
p53 expression, localisation and function (12) and also possibly plays a role in 
transcription regulation within the nucleus of the cell. (17). 
CALR protein has been found to act as a molecular chaperone within the ER 
where it binds to the newly synthesised glycoproteins thereby preventing their 
aggregation and facilitating correct protein folding and subsequent function. 
CALR works in harmony with calnexin and ERp57 to create a protein forming 
cycle which controls protein folding.  (3) 
Waser et al determined that the CALR gene, which regulates the CALR protein, 
is activated by A23187-, bradykinin dependent Ca2+ depletion of intracellular 
calcium or thapsigargin in both in vivo and in vitro experiments (17). It has also 
been determined that CALR mRNA and protein levels increase according to 
endoplasmic reticulum store depletion.   
(B) Extracellularly 
Outside the endoplasmic reticulum, CALR protein has been detected on the cell 
surface and within the cytosol. (18) Here it modulates the expression of N-
cadherin and vinculin, two transmembrane proteins which are vital in cell 
adhesion. It also modulates the transcriptional activity of steroid receptors and 
other transcription factors and mediates the nuclear export of the glucocorticoid 
receptor. (3) 
It has also been found that early disruption of the CALR protein can be 
embryonically lethal, showing decreased ventricular wall thickness and 
intertrabecular recesses within the ventricular walls. (19) This occurs due to the 
disruption of CALR which leads to abnormal ER calcium availability thereby 
impairing myofibrillogenesis. (20)  
From this we can conclude that the CALR protein is a multifunctional protein 
which acts intracellularly where it plays a vital role in calcium homeostasis and 
also facilitates protein folding, quality and control. Extracellularly CALR plays 
a vital role in cell adhesion, modulation of gene expression, nuclear export, 
cardiogenesis and immunogenic cell death. (3) 
 
Mutation of the CALR gene 
In 2005, JAK2-V617F was discovered. Prior to this minimal information was 
available on the molecular pathogenesis of myeloproliferative neoplasms 
(MPN). In 2013, two studies carried out by Nangalia et al and Klampf et al (21,22) 
discovered somatic recurrent insertions/deletions which exclusively affected 
exon 9 in the CALR gene in 70-84% of wild type JAK2 and MPL Primary 
Myelofibrosis and essential thrombocytopenia. (21,22,23) 
Klampfl et al (22) discovered the CALR gene mutation whilst carrying out 
exome sequencing on tumour samples on MPN patients DNA and matched CD3 
+ T lymphocyte in six patients lacking JAK2 and MPL mutations. (22) A 
recurring mutation was noted on the CALR gene. Further analysis by 
polymerase chain reaction found that 25-35% of patient who did not possess 
JAK2 or MPL mutations had mutations in the CALR gene. (22,24). Subsequent 
studies have also found that CALR mutations were detected in 60-80% of 
patients with essential thrombocythaemia (ET) and primary myelofibrosis 
(PMF) who lacked JAK2 and MPL mutations. (23) CALR mutations were not 
detected in patients with polycythaemia vera. (PV) (22,25) 
Nangalia et al performed exome sequencing on 151 patients with MPN 
and identified CALR mutations in 70-84% of samples of MPN without JAK2 
mutations. (21) They then further expanded their investigation to patients with 
other haematological malignancies and non-haematological malignancies and 
found that this mutation occurs at low rates in myeloid malignancies and not at 
all in non-haematological malignancies. (21) 
Greater than 50 different CALR mutations have been detected to date, but 
the most common mutation types detected are type 1 variant/mutation 
(p,L367fs*47) which results from 52-bp deletion, and type 2 variant/mutation 
(p.K385fs*47) which results from a 5-bp TTGTC insertion within exon 9 of the 
gene. (5,25,26). Of patients, 45-53% harbour type 1 mutations and 32-41% of 
patients harbour type 2 mutations. (20). Both types of mutations cause a single 
base pair frameshift which results in the formation of a novel mutant C-
Terminal peptide composed of a minimal 36 amino acid stretch which replaces 
the 27 amino acids which are lost from the normal sequence. (20) The last four 
amino acids of calreticulin (KDEL), which contain the ER retention signal 
become positively charged, the reticulum targeting KDEL sequence is abolished 
thereby disturbing it cellular localisation. (23) 
A non mutated CALR C terminus is largely negatively charged, whereas the 
mutated terminus contains positively charged amino acids. Type 1 mutations 
eliminate all negatively charged amino acids whereby type 2 mutations maintain 
up to half of the positively charged amino acids. (26) By eliminating the negative 
charge on this C terminus the Ca 2+ binding function is impaired and the KDEL 
modif is lost therefore mutant CALR may have an altered subcellular 
localisation (22,24,26). 
In MPN, several studies have found CALR mutations in patients which are 
located in haematopoietic stem and progenitor cells and are believed to activate 
the STAT5 signalling pathway. (18) By causing cytokine hypersensitivity, 
suggesting that mutated CALR has the ability to activate the haemopoietic 
cytokine signalling pathway (12).  
 
 
Role of CALR in Pathological Conditions 
The Philadelphia negative myeloproliferative disorders are a group of disorders 
which include PV, ET and PMF. PMF is characterised by abnormal 
proliferation of megakaryocytes, abnormal stem cell trafficking, deposition of 
fibrous connective tissues in the bone marrow and extramedullary 
haematopoiesis (27). ET is characterised by platelet overproduction resulting 
from hyperproliferation of megakaryocytes. PV is characterised by 
hyperproliferation of predominantly erythroid cells.  (12).  
Specific genetic mutations have been associated with myeloproliferative 
neoplasms. JAK2 mutations are almost invariable in PV. 50-60% of patients 
with PMF or ET harbour the JAK2 mutation and up to 10% harbour the 
Myeloproliferative leukaemia (MPL) virus oncogene. (22,28) Recently, alternative 
mutations have been detected in patients with sporadic ET or PMF without 
JAK2 or MPL alterations. (29). 
How the mutated CALR, which is characterised by lower calcium binding 
activity and is independent of the endoplasmic reticulum motif KDEL (30), 
causes the overproduction of abnormal megakaryocytes and platelets is the 
major question. It has been hypothesised that the pathogenetic effects have been 
found to be somewhat attributable to the JAK/STAT signalling. This is 
supported by findings that showed a link between increased STAT5 
phosphorylation and CALRdel52 mutation in interleukin 3 dependent murine 
Ba.F3 cells. This resulted in cells to become cytokine independent. (20) Recent 
studies in cell lines and mice of the mutant protein show the mutant activates 
the downstream pathways with cMPL(31,32) and show an mechanism where a 
mutated chaperone activates cytokine receptor signalling(33). A novel 
mechanism is conceived where the mutant chaperone CALR constitutively 
activates receptor signalling through the abnormal interaction with MPL (34). 
 
A. CALR in primary myelofibrosis  
In patients with PMF, CALR mutations are associated with better survival 
compared to those with JAK2 or MPL mutations. (35) However, Tefferi et al 
discovered that the prognostic benefit of CALR mutations is limited to patient 
with type 1 (52-bp) or type 1 variant of the CALR mutation rather than those 
with type 2 or type 2 variant mutations (36).  The CALRdel52 mutation was 
found to be more frequent in PMF than ET. (19) The mutational frequencies of 
CALR in PMF have been found to be between 25-35% and one study found that 
27% of patients harboured a CALR mutation, with 80% harbouring type 1 and 
11% harbouring type 2. (22,35,36) In PMF poor patient survival has been 
associated with the presence of ASXL1 mutations and also in patients with 
TYPE 2 CALR mutations (38), with the absence of such mutations associated 
with a favourable survival rate.   
Patient phenotype: 
PMF patients with the CALR mutations are preferentially male, younger 
in age (less than 60 years of age), (24) have an higher haemoglobin, leucocyte 
count, platelet count and an improved overall survival rate (37) In comparison to 
patients with JAK2 and MPL mutations. (9). A lower incidence of spliceosome 
mutations have also been noted in these patients. (29) Patients with CALR 
mutations were noted to be less anaemic, thereby requiring fewer transfusions 
(24). No evolutionary differences were noted between patients with the CALR 
mutations and JAK2 mutated genes (30). See table 1 for further details on patient 
phenotypes. 
 
B. CALR in essential thrombocytopenia 
The frequency of CALR mutations in ET ranges between 15-24% (30). Two 
variants of the CALR mutation exist in ET, type 1, a 52-bp deletion 
(p.L367fs*46) and type 2a 5-bp TTGTC insertion (p.K385fs*47).  Recently the 
frequencies of type 1 and type 2 mutations in ET have been found to be 46% 
and 38% respectively (36). Type 2 has been associated with a high circulating 
blast percentage, increased platelet count (28) leucocyte count, dynamic 
international prognostic scoring system and poorer survival rate. (29).  
Patient phenotype 
Patient with CALR mutated ET were found to be male, younger in age 
(less than 60 years), higher platelet count (>1000 x 109/l), lower leucocyte 
count, lower haemoglobin and a lower incidence of cardiovascular 
complications or thrombosis risk than their JAK2 mutated counterparts (9,29,37).  
No patient with the CALR mutation to date has been found to evolve from PET 
to PV or acute leukaemia (38), whereas 29% of patients with JAK2 mutation at 
15 years were found to evolve. (30) Patients harbouring CALR mutations have 
been found to have a higher incidence of myelofibrotic transformation as 
opposed to their JAK2 mutated counterparts (37). In such patients pegylated 
interferon has been noted to have a positive clinical effect, the allele burden was 
noted to decrease form 43% - 19% with this treatment and therefore could be 
used as a biomarker to monitor therapeutic response. See table 1 for further 
details on patient phenotypes.  
 
Table 1: A comparison of patient phenotypes with both CALR and JAK2 
mutations in ET and PMF(17,27) 
 ET  - 
CALR 
mutation 
ET- 
JAK2 
mutation 
PMF – CALR 
mutation 
PMF – JAK2 
mutation 
Age Younger <50 Older >50 Younger <50 Older >60 
Gender male female male male 
Platelets (x109/l) Higher >800 Lower <800 Lower (<400) Higher (>400) 
Haemoglobin 
(g/l) 
Lower <140 Higher >140 Lower (<120) Higher (>120) 
Leucocytes 
(x109/l) 
Lower (<8.5) Higher(>8.5) Higher (>9) Lower (<9) 
Thrombosis Risk lower higher lower higher 
Survival longer Worse prognosis longer Worse 
prognosis 
 
C . CALR mutation in non-haematological conditions 
Calreticulin has been detected in the serum of patients suffering from Systemic 
Lupus Erythematous, Sjogren’s disease, coeliac disease, rheumatic disease and 
also various parasitic diseases. CALR has been found to associate with 
ribonucleoprotein complex Ro/SSA, an autoantigen which is found in most 
patients with Sjogren’s and SLE. It has also been found to interact with C1q, the 
first component of complement, thereby activating the classical complement 
pathway. (39) 
Diagnostic Criteria 
The revolutionary discovery of the CALR mutation in MPN patients harbours 
prognostic relevance. The following tables illustrate the WHO 2008 diagnostic 
criteria for PV, ET and PMF. (40) 
 
Table 2: The 2008 WHO diagnostic criteria for Essential Thrombocytopenia(40) 
Thrombocytosis >450x109 
Enlarged, mature megakaryocytes on bone marrow biopsy with no significant increase or left-
shift of granulopoiesis or erythropoiesis 
Patient does not meet the criteria for: 
PMF, PV, MDS, BCR-ABL1-positive chronic myelogenous leukemia or another myeloid 
neoplasm 
Presence of JAK2 V617F or other clonal marker or in its absence no evidence for a reactive 
thrombocytosis 
 
All four must be present for a patient to be diagnosed with ET. 
 
Table 3: The 2008 WHO diagnostic criteria for Polycythaemia Vera(40) 
Major Criteria Minor Criteria 
Hemoglobin >185 g/L in men, >165 g/L in 
women or other evidence of increased red 
cell volume 
Bone marrow biopsy showing hyper-
cellularity for age with trilineage growth 
(panmyelosis) with prominent erythroid, 
granulocytic and megakaryocytic 
proliferation 
 
Presence of JAK2 V617F or other 
functionally similar mutation (such as JAK2 
exon 12 mutation) 
Serum erythropoietin level below the 
reference range for normal 
 
 Endogenous erythroid colony formation in 
vitro 
 
For a patient to be diagnosed with PV they must possess both major criteria or 
the first major criteria and two minor criteria.  
Table 4: The 2008 WHO diagnostic criteria for Primary Myelofibrosis(40) 
Major criteria Minor Criteria 
Megakaryocyte proliferation and atypia, 
usually with either reticulin and/or collagen 
fibrosis 
Leukoerythroblastosis 
Presence of JAK2 V617F or other clonal 
marker (eg MPL W515K/L), OR in absence 
of a clonal marker, no evidence that the 
marrow fibrosis or other changes are reactive 
Increase in serum LDH 
Does NOT meet WHO criteria for any of the 
following: PV, BCR-ABL1+chronic 
myelogenous leukemia, MDS, or other 
myeloid neoplasm 
Anaemia 
Splenomegaly 
 
Diagnosis of PML requires all three major criteria plus two minor criteria.   
CALR mutation does not feature in these criteria due to its recent discovery. Its 
discovery not only provides new insights into the molecular basis of MPN but 
also new molecular approaches to their diagnosis and therefore inclusion into 
the above diagnostic criteria will be part of revised criteria of these diseases (41). 
Conclusion 
William Dameshek first described myeloproliferative disorders in 1951 as a 
‘related group of disease with a shared myelostimulatory factor accounting for 
overlapping clinical and laboratory features (42). The JAK2 V617F gene 
mutation was subsequently discovered 55 years later and noted to be present in 
90-95% of PV, 40-60% of ET and PMF cases. This discovery has proved 
revolutionary in the diagnosis, understanding and clinical management of these 
patients. The recent discovery of the CALR gene mutation has further 
revolutionised our understanding of the myeloproliferative disorders. By 
identifying the role of CALR mutation in ET and PMF we have enabled the 
patients presenting with these conditions to be placed into one of two 
subgroups, A. CALR mutant ET/PMF which has an indolent clinical course and 
B. PMF/ET with non mutated JAK2, CALR and MPL which is a very aggressive 
myeloid neoplasm. (27) New studies have since determined that PCR 
amplification, followed by fragment length analysis can be used in patients with 
MPN for CALR mutations to determine their mutant allele burden (43) which 
could allow early diagnosis of a more aggressive phenotype and subsequent 
early or type specific management and therefore increase patient survival.  
The discovery of CALR mutations has enabled us to firstly distinguish that ET 
patients who present with the CALR mutation are younger in age, male gender 
increased platelet counts and lower haemoglobin and leucocyte counts. These 
patients also have a significantly lower thrombosis risk and therefore may not 
require the introduction of antiplatelet therapy or hydroxyurea. Research carried 
out in 2015 by Alvaraz-Larren et al on CALR positive ET patients who are at 
low risk of thrombosis determined that such patients did not benefit from low 
dose aspirin as the risk of bleeding offset the reduction in the rate of thrombosis 
(44).  Hydroxyurea was not tested in this study. Additionally, these patients have 
been found to show a reduction in allele burden with the use of pegylated 
interferon thereby allowing this to be used as a biomarker for therapeutic 
response in these patients. (25) PMF patients presenting with CALR mutations are 
now known to have a better prognosis and lower risk of evolution to acute 
leukaemia than patients with JAK2 mutations. By discovering this mutated 
CALR gene we now can account for the genetic mutation in up to 90% of 
patients who present with MPN, decipher accurate management for these 
patients, thereby increasing patient safety and improving disease prognosis.  
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Legends to Figures 
 
Figure 1  
This diagram illustrates the human gene with 9 exons. The CALR gene is located on exon 9. 
(Adapted from Michalak et al)(5) 
 
 
Figure 2:  
This diagram illustrates the three functional domains of the CALR gene and their various 
functions. The N domain is where interaction with the DNA binding site of steroid receptors 
and α integrins takes place. The P domain is rich is proline and forms lectin like structures 
which are responsible for CALR’s protein binding function and also binds Ca 2+ with high 
affinity. The C domain is rich in acidic amino acids and regulates calcium levels within the 
endoplasmic reticulum. This domain terminates with the KDEL ER sequence.         
